Related Experiment Video

Updated: Aug 13, 2026

Development and Application of Rapamycin-regulated Tyrosine Phosphatases
06:56

Development and Application of Rapamycin-regulated Tyrosine Phosphatases

Published on: September 6, 2024

Rapamycin disrupts cyclin/cyclin-dependent kinase/p21/proliferating cell nuclear antigen complexes and cyclin D1

Mary Law1, Elizabeth Forrester, Anna Chytil

  • 1Department of Pharmacology and Therapeutics and the Shands Cancer Center, University of Florida, 1600 Southwest Archer Road, Gainesville, FL 100267, USA.

Cancer Research
|January 21, 2006
PubMed

Insights

Rapamycin derivatives, like everolimus, show promise in cancer therapy by inhibiting tumor growth. This study reveals they work by disrupting cyclin D1/Cdk2 complexes, crucial for cell cycle progression.

Area of Science:

  • Oncology
  • Molecular Biology
  • Biochemistry

Background:

  • Rapamycin and its derivatives are potential anticancer drugs, but their precise mechanisms of action, including cell cycle arrest and tumor growth inhibition, remain unclear.
  • Understanding these mechanisms is crucial for optimizing their therapeutic use, particularly in breast cancer.

Purpose of the Study:

  • To elucidate the molecular mechanisms by which rapamycin and its derivatives induce cell cycle arrest and inhibit tumor growth.
  • To investigate the role of cyclin-dependent kinase (Cdk) complexes and their regulators in mediating the effects of rapamycin.

Main Methods:

  • Biochemical analysis of human mammary tumor cell lines treated with rapamycin.
  • Investigating the effects of cyclin D1 overexpression and utilizing novel cyclin D1-Cdk2 fusion proteins.
  • In vivo studies using mouse mammary tumor models treated with the rapamycin derivative RAD001 (everolimus).

Main Results:

  • Rapamycin treatment led to decreased cellular p21 levels and reduced p21 association with Cdk2 and Cdk4 complexes.
  • Overexpression of cyclin D1 reversed rapamycin's effects, correlating with increased p21, enhanced p21-Cdk2 association, and stabilized cyclin D1/Cdk2/p21/PCNA complexes.
  • Reversal of rapamycin action required complex formation and kinase activity, while RAD001 inhibited tumor growth by disrupting cyclin D1/Cdk2 complexes.

Conclusions:

  • Rapamycin derivatives exert anticancer effects by down-regulating p21 and disrupting cyclin D1/Cdk2 complexes, thereby inhibiting cell proliferation.
  • These findings highlight the critical role of cyclin D1-Cdk2 complexes in mediating rapamycin's antiproliferative activity.
  • The study provides insights into the therapeutic potential of rapamycin derivatives in breast cancer treatment by targeting specific molecular pathways.

More Related Videos

A Semi-Quantitative Drug Affinity Responsive Target Stability (DARTS) assay for studying Rapamycin/mTOR interaction05:28

A Semi-Quantitative Drug Affinity Responsive Target Stability (DARTS) assay for studying Rapamycin/mTOR interaction

Published on: August 27, 2019

Spatio-Temporal Manipulation of Small GTPase Activity at Subcellular Level and on Timescale of Seconds in Living Cells10:27

Spatio-Temporal Manipulation of Small GTPase Activity at Subcellular Level and on Timescale of Seconds in Living Cells

Published on: March 9, 2012

Related Concept Videos

Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Inhibition of CDK Activity02:34

Inhibition of CDK Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Negative Regulator Molecules01:23

Negative Regulator Molecules

Positive regulators allow a cell to advance through cell cycle checkpoints. Negative regulators have an equally important role as they terminate a cell’s progression through the cell cycle—or pause it—until the cell meets specific criteria.
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a rapamycin-insensitive companion...
DNA Damage can Stall the Cell Cycle02:36

DNA Damage can Stall the Cell Cycle

In response to DNA damage, cells can pause the cell cycle to assess and repair the breaks. However, the cell must check the DNA at certain critical stages during the cell cycle. If the cell cycle pauses before DNA replication, the cells will contain twice the amount of DNA. On the other hand, if cells arrest after DNA replication but before mitosis, they will contain four times the normal amount of DNA. With a host of specialized proteins at their disposal,cells must use the right protein at...